American Society of Clinical Oncology

SHERPA: White

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Noy
    Noy
  4. Hamlin
    Hamlin
  5. Palomba
    Palomba
  6. Moskowitz
    Moskowitz
  7. Schoder
    Schoder
  8. Yahalom
    Yahalom
  9. Kumar
    Kumar
  10. Drullinsky
    Drullinsky

Groups

  1. Center for Hematologic Malignancies (84)
  2. Department of Medicine (84)
  3. Hematologic Malignancies, Division of (84)
  4. Lymphoma (84)
  5. Population Sciences Research Program (21)
  6. Survivorship Research (19)
  7. Epidemiology and Biostatistics (16)
  8. Radiology, Department of (15)
  9. Biostatistics Service (13)
  10. Molecular Imaging and Therapy Service (12)
Search Within
  1. "Andrew Zelenetz"
Formats
  1. Meeting Abstract (54)
  2. Journal Article (30)
Groups
  1. Center for Hematologic Malignancies (84)
  2. Department of Medicine (84)
  3. Hematologic Malignancies, Division of (84)
  4. Lymphoma (84)
  5. Population Sciences Research Program (21)
  6. Survivorship Research (19)

More Groups

People
  1. Andrew Zelenetz (84)
  2. Craig Moskowitz (24)
  3. David Straus (18)
  4. Ariela Noy (17)
  5. Paul Hamlin (17)
  6. Steven Horwitz (17)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (5)
  4. 2020 (6)
  5. 2019 (3)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (82)
  2. American Society of Clinical Oncology Educational Book (1)
  3. Journal of Oncology Practice (1)

Results (84)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment
    Meeting Abstract

    Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I. W.; Alencar, A. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma
    Journal Article

    Wang, M. L.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; Flinn, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL
    Meeting Abstract

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; López-Jiménez, J.; Reddy, N.; Mengarelli, A.; Phillips, T. J.; Musuraca, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies
    Meeting Abstract

    Soumerai, J. D.; Jagadeesh, D.; Salman, H. S.; Lossos, I. S.; Asch, A. S.; Reddy, N.; Kenkre, V. P.; Pagel, J. M.; Persky, D. O.; Awan, F. T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of the PI3K delta inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24)
    Meeting Abstract

    Pagel, J. M.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H. S.; Kenkre, V. P.; Soumerai, J. D.; Llorin-Sangalang, J.; Gorbatchevsky, I.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice
    Meeting Abstract

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save